PD-L1 based immunotherapy
The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising PD-L1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases.
1. A vaccine composition comprising:
a) an immunogenically-active peptide fragment consisting of a consecutive sequence of in the range of 8 to 50 amino acids of the PD-L1 polypeptide of SEQ ID NO: 1, wherein at the most 3 amino acids may be substituted, and wherein said peptide fragment comprises a peptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:12 and SEQ ID NO:15; and
b) an adjuvant.
2. The vaccine composition according to claim 1 , wherein the vaccine composition comprises an immunogenically active peptide fragment consisting of a consecutive sequence of the polypeptide PD-L1 of SEQ ID NO:1 of in the range of from 8 to 20 amino acids, wherein at the most 2 amino acids may be substituted.
3. The vaccine composition according to claim 1 , wherein the vaccine composition comprises an immunogenically active peptide fragment consisting of at the most 40 amino acid residues.
4. The vaccine composition according to claim 1 , wherein the vaccine composition comprises an immunogenically active peptide fragment consisting of at the most 20 amino acid.
5. The vaccine composition according to claim 1 , wherein the vaccine composition comprises an immunogenically active peptide fragment, wherein said peptide fragment comprises a peptide selected from the group consisting of SEQ ID NO: 2, 12 and 15.
6. The vaccine composition according to claim 1 , wherein the vaccine composition comprises an immunogenically active peptide fragment selected from the group consisting of SEQ ID NO: 2, 3 and 4.
7. The vaccine composition according to claim 1 , comprising said immunogenically active peptide fragment, wherein said peptide fragment is restricted by a MHC Class I molecule.
8. The vaccine composition according to claim 1 , comprising said immunogenically active peptide fragment, wherein said peptide fragment is restricted by a MHC Class II molecule.
9. The vaccine composition according to claim 1 , wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants and imidazochinilines.
10. A kit-of-parts comprising:
(a) the vaccine composition according to claim 1 , and
(b) a composition comprising at least one second active ingredient.
11. A method of treating a clinical condition characterized by the expression of PD-L1, the method comprising administering to an individual suffering from said clinical condition an effective amount of the composition according to claim 1 , wherein the clinical condition is cancer.
12. The method according to claim 11 , where the cancer is a tumor forming cancer disease.
13. The vaccine composition according to claim 1 , wherein the vaccine composition comprises an immunogenically active peptide fragment consisting of at the most 30 amino acid residues.
14. The vaccine composition according to claim 1 , wherein the peptide fragment comprises or consists of SEQ ID NO:23.
15. The vaccine composition according to claim 1 , wherein the peptide fragment comprises or consists of SEQ ID NO:24.